Literature DB >> 29580681

Head-to-tail macrocyclization of cysteine-free peptides using an o-aminoanilide linker.

Takumi Ohara1, Masato Kaneda1, Tomo Saito1, Nobutaka Fujii1, Hiroaki Ohno1, Shinya Oishi2.   

Abstract

A head-to-tail macrocyclization protocol for the preparation of cysteine-free cyclic peptides was investigated. The o-aminoanilide linker constructed in the peptide sequence by a standard Fmoc-based peptide synthesis procedure was subjected to nitrite-mediated activation under acidic conditions toward N-acyl benzotriazole as the active ester species. The subsequent cyclization smoothly proceeded by neutralization in the presence of additives such as 1-hydroxybenzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt) to afford the expected cyclic pentapeptide, a CXCR4 antagonist. The cyclization efficiencies were dependent on the precursor open-chain sequence. The application of this step-wise activation-cyclization protocol to microflow reaction systems is also described.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CXCR4 antagonist; Chemokine; Cyclic peptide; Macrocyclization; Microflow reaction

Mesh:

Substances:

Year:  2018        PMID: 29580681     DOI: 10.1016/j.bmcl.2018.03.027

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.

Authors:  Jen-Shin Song; Chih-Chun Chang; Chien-Huang Wu; Trinh Kieu Dinh; Jiing-Jyh Jan; Kuan-Wei Huang; Ming-Chen Chou; Ting-Yun Shiue; Kai-Chia Yeh; Yi-Yu Ke; Teng-Kuang Yeh; Yen-Nhi Ngoc Ta; Chia-Jui Lee; Jing-Kai Huang; Yun-Chieh Sung; Kak-Shan Shia; Yunching Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

Review 2.  Amide Bonds Meet Flow Chemistry: A Journey into Methodologies and Sustainable Evolution.

Authors:  Antonella Ilenia Alfano; Heiko Lange; Margherita Brindisi
Journal:  ChemSusChem       Date:  2022-02-01       Impact factor: 9.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.